Marker Therapeutics, Inc.

Monthly Archives: May 2015

Phase I Study in Ovarian & Breast Cancer Published in Abstracts of 2015 ASCO Annual Meeting

SEATTLE, Wash., May 15, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), is pleased to announce that an Abstract on a Phase I Study on the Safety and Immunogenicity of a folate receptor alpha (FRAα) peptide vaccine has been published in J Clin.
Read More